Patent · US Active

Immunogen providing an extended protective lifetime against respiratory syncytial virus (RSV) and vaccines thereof

US12246063B2 · kind B2 · utility

0Cited by

9References

17Claims

0Family size

Assignee

Trellis Bioscience, Inc. · US

Inventors

Milton J. Friedman · Belmont, US
Lawrence M. Kauvar · San Francisco, US

Key dates

Filing date	Feb 5, 2021
Grant date	Mar 11, 2025
Priority date	—
Expiry date	Nov 13, 2043

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2760/18534
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Improvements to vaccines against RSV include G protein CCD portions complexed with mAb that block interaction with CX3C-R and modified forms of mAb to prolong serum half-life, as well as inhalable vaccines.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.